Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTX NASDAQ:INSM NASDAQ:ONC NASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTXBioNTech$112.55-0.9%$109.42$81.20▼$131.49$27.06B1.23932,969 shs398,523 shsINSMInsmed$127.39-0.3%$103.62$60.40▼$130.13$26.93B0.952.84 million shs3.43 million shsONCBeOne Medicines$319.32-0.6%$274.62$170.99▼$330.63$35.00B0.27438,354 shs595,229 shsVRNAVerona Pharma PLC American Depositary Share$105.79+0.5%$99.27$24.50▼$105.85$9.01B0.122.28 million shs1.21 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTXBioNTech0.00%+1.67%+3.18%+16.07%+33.26%INSMInsmed0.00%+16.66%+24.61%+88.27%+67.72%ONCBeOne Medicines0.00%+11.51%+9.10%+37.70%+32,135,999,900.00%VRNAVerona Pharma PLC American Depositary Share0.00%-0.01%+0.35%+45.04%+282.94%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNTXBioNTech1.6178 of 5 stars3.42.00.00.01.90.80.0INSMInsmed4.098 of 5 stars2.54.00.04.33.81.70.6ONCBeOne Medicines0.6398 of 5 stars1.50.00.00.01.91.70.6VRNAVerona Pharma PLC American Depositary Share2.3672 of 5 stars2.15.00.00.02.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTXBioNTech 2.76Moderate Buy$135.8020.66% UpsideINSMInsmed 2.94Moderate Buy$129.571.71% UpsideONCBeOne Medicines 3.00Buy$330.893.62% UpsideVRNAVerona Pharma PLC American Depositary Share 2.14Hold$109.003.03% UpsideCurrent Analyst Ratings BreakdownLatest VRNA, ONC, BNTX, and INSM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025BNTXBioNTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$138.00 ➝ $136.008/14/2025INSMInsmedTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$126.00 ➝ $139.008/14/2025INSMInsmedStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$121.00 ➝ $145.008/13/2025INSMInsmedThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$114.00 ➝ $142.008/13/2025INSMInsmedMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$126.008/13/2025INSMInsmedJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$129.00 ➝ $148.008/13/2025INSMInsmedMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$130.00 ➝ $165.008/12/2025INSMInsmedWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$130.00 ➝ $140.008/8/2025INSMInsmedUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$124.00 ➝ $133.008/8/2025INSMInsmedRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$108.00 ➝ $120.008/8/2025VRNAVerona Pharma PLC American Depositary ShareZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTXBioNTech$2.98B9.09N/AN/A$87.61 per share1.28INSMInsmed$363.71M74.04N/AN/A$1.60 per share79.62ONCBeOne Medicines$3.81B9.19N/AN/A$34.10 per share9.36VRNAVerona Pharma PLC American Depositary Share$42.28M213.01N/AN/A$2.56 per share41.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTXBioNTech-$719.92M-$1.60N/AN/AN/A-12.20%-1.84%-1.59%11/3/2025 (Estimated)INSMInsmed-$913.77M-$5.71N/AN/AN/A-259.82%-195.37%-49.49%10/30/2025 (Estimated)ONCBeOne Medicines-$644.79M-$1.73N/A449.75N/A-3.89%-1.22%-0.72%N/AVRNAVerona Pharma PLC American Depositary Share-$173.42M-$0.99N/A3,526.33N/A-36.62%-21.12%-9.07%11/3/2025 (Estimated)Latest VRNA, ONC, BNTX, and INSM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025INSMInsmed-$1.30-$1.70-$0.40-$1.70$104.06 million$107.42 million8/6/2025Q2 2025ONCBeOne Medicines$0.48$0.84+$0.36$0.84$1.24 billion$1.32 billion8/6/2025Q2 2025VRNAVerona Pharma PLC American Depositary Share-$0.01$0.13+$0.14$0.13$90.41 million$103.14 million8/4/2025Q2 2025BNTXBioNTech-$1.41-$1.60-$0.19-$1.82$161.26 million$306.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNTXBioNTechN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/AONCBeOne MedicinesN/AN/AN/AN/AN/AVRNAVerona Pharma PLC American Depositary ShareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTXBioNTech0.018.618.48INSMInsmed0.456.686.33ONCBeOne Medicines0.041.951.72VRNAVerona Pharma PLC American Depositary Share0.8710.7110.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTXBioNTech15.52%INSMInsmedN/AONCBeOne Medicines48.55%VRNAVerona Pharma PLC American Depositary Share85.88%Insider OwnershipCompanyInsider OwnershipBNTXBioNTech19.20%INSMInsmed3.00%ONCBeOne Medicines6.62%VRNAVerona Pharma PLC American Depositary Share4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTXBioNTech6,772240.40 million194.24 millionOptionableINSMInsmed1,271211.38 million205.03 millionOptionableONCBeOne Medicines11,000109.60 million102.34 millionN/AVRNAVerona Pharma PLC American Depositary Share3085.13 million81.05 millionOptionableVRNA, ONC, BNTX, and INSM HeadlinesRecent News About These CompaniesTokio Marine Asset Management Co. Ltd. Makes New $698,000 Investment in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)August 18 at 5:09 AM | marketbeat.comLPL Financial LLC Purchases 20,500 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)August 18 at 3:06 AM | marketbeat.comLord Abbett & CO. LLC Makes New Investment in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)August 17 at 5:48 AM | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Stock Holdings Trimmed by Aisling Capital Management LPAugust 16 at 8:43 AM | marketbeat.comVirtu Financial LLC Makes New Investment in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)August 14, 2025 | marketbeat.comAigen Investment Management LP Purchases New Shares in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)August 13, 2025 | marketbeat.comAll You Need to Know About Verona Pharma (VRNA) Rating Upgrade to BuyAugust 12, 2025 | zacks.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) is Knott David M Jr's 8th Largest PositionAugust 12, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (VRNA) Expected to Announce Quarterly Earnings on ThursdayAugust 12, 2025 | americanbankingnews.comWatchtower Advisors LP Reduces Position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)August 9, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) is Vivo Capital LLC's 2nd Largest PositionAugust 9, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (VRNA) to Release Earnings on ThursdayAugust 7, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Director James Aloysius Brady Sells 824 SharesAugust 6, 2025 | marketbeat.comInsider Selling: Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Director Sells 1,808 Shares of StockAugust 6, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Director Sells $25,018.56 in StockAugust 6, 2025 | marketbeat.comInsider Selling: Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) Director Sells 3,608 Shares of StockAugust 6, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Director Vikas Sinha Sells 4,328 SharesAugust 6, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Director Sells $124,356.96 in StockAugust 6, 2025 | marketbeat.comInsider Selling: Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Sells 9,584 Shares of StockAugust 6, 2025 | marketbeat.comVerona Pharma PLC American Depositary Share (NASDAQ:VRNA) Director Sells $142,017.12 in StockAugust 6, 2025 | marketbeat.comMartin Edwards Sells 10,808 Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) StockAugust 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesApple Stock: Big Earnings, Small Move—Time to Buy?By Chris Markoch | August 1, 2025Tesla’s Pennant Just Snapped: Here’s What It Means for the StockBy Sam Quirke | August 14, 2025PEGA Surges 14%: There's Still Time to Ride This GenAI InnovatorBy Leo Miller | July 27, 2025Alphabet Gains Momentum as Sentiment on Wall Street ImprovesBy Ryan Hasson | August 1, 20253 Retailers Poised to Outmaneuver Tariff and Recession ConcernsBy Nathan Reiff | July 20, 2025VRNA, ONC, BNTX, and INSM Company DescriptionsBioNTech NASDAQ:BNTX$112.55 -0.97 (-0.85%) Closing price 04:00 PM EasternExtended Trading$112.70 +0.15 (+0.13%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.Insmed NASDAQ:INSM$127.39 -0.41 (-0.32%) Closing price 04:00 PM EasternExtended Trading$127.81 +0.42 (+0.33%) As of 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.BeOne Medicines NASDAQ:ONC$319.32 -2.04 (-0.63%) As of 04:00 PM EasternBeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.Verona Pharma PLC American Depositary Share NASDAQ:VRNA$105.79 +0.52 (+0.49%) Closing price 04:00 PM EasternExtended Trading$105.53 -0.26 (-0.24%) As of 04:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Whirlpool A Screamin’ Buy in 2025? Signs Say Yes Rocket Stock Just Broke Out, But EPS Growth Still Isn't Priced In Buffett Makes Big Moves Outside of UNH: A Buy and Sell Breakdown Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Is Reddit Stock Too Hot, or Just Right? Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple Why Arista's Blowout Q2 Is Good News for Chip-Giant Broadcom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access